Medicare Coverage of Amyloid PET: Implications for Clinical Practice

References

1. 1.↵
   2023 Alzheimer’s disease facts and figures. Alzheimers Dement 2023;19:1598–695 doi:10.1002/alz.13016 pmid:36918389

   CrossRefPubMed
2. 2.↵
   1. Jack CR Jr.,
   2. Bennett DA,
   3. Blennow K, et al

   . NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018;14:535–62 doi:10.1016/j.jalz.2018.02.018 pmid:29653606

   CrossRefPubMed
3. 3.↵
   1. Rabinovici GD,
   2. Gatsonis C,
   3. Apgar C, et al

   . Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019;321:1286–94 doi:10.1001/jama.2019.2000 pmid:30938796

   CrossRefPubMed
4. 4.↵
   1. Smith NM,
   2. Ford JN,
   3. Haghdel A, et al

   . Statistical parametric mapping in amyloid positron emission tomography. Front Aging Neurosci 2022;14:849932 doi:10.3389/fnagi.2022.849932 pmid:35547630

   CrossRefPubMed